|
Outcome and follow-up of glioblastoma patients treated with bevacizumab based therapy in 2nd lign treatment. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Menarini; Novartis; Servier |
Consulting or Advisory Role - Menarini; Novartis; SERVIER |
Speakers' Bureau - Amgen; Novartis |
Research Funding - Novartis (Inst) |
Travel, Accommodations, Expenses - Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |